2-(mesyloxy)phenol | 59722-34-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(mesyloxy)phenol
• 英文别名: catechol mesylate；2-mesyloxyphenol；2-hydroxyphenyl methanesulfonate；2-(methanesulfonyloxy)-phenol；phenol O-mesylate；2-(Methansulfonyloxy)-phenol；(2-hydroxyphenyl) methanesulfonate
• CAS: 59722-34-8
• 化学式: C₇H₈O₄S
• 分子量: 188.204
• InChiKey: CIMCLQVPRYEIOM-UHFFFAOYSA-N

物化性质

• 沸点：
  337.9±34.0 °C(Predicted)
• 密度：
  1.416±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(mesyloxy)phenol 在 三苯基膦 、 sodium iodide 、 偶氮二甲酸二乙酯 作用下， 以 乙醚 、 丙酮 为溶剂， 反应 21.0h， 生成 (R)-1-iodo-3-(2-mesyloxyphenoxy)-3-phenylpropane
  参考文献：
  名称：

  Synthesis and C-11 labeling of three potent norepinephrine transporter selective ligands ((R)-nisoxetine, lortalamine, and oxaprotiline) for comparative PET studies in baboons

  摘要：

  Three potent antidepressants, (R)-nisoxetine, lortalamine, and oxaprotiline, with high affinity and high selectivity for the norepinephrine transporter (NET) were synthesized and radiolabeled with C-11 via [C-11]methylation. The reference compounds and their corresponding normethyl precursors were synthesized via multi-step synthetic approaches. The radiochemical syntheses were performed by simple alkylation of the corresponding normethyl precursors with no-carrier-added [C-11]CH3I in DMF. After HPLC purification, (R)-[N-(CH3)-C-1]nisoxetine, [C-11]lortalamine, and [1 v C]oxaprotiline were obtained in 63-97% radiochemical yields, whereas (R)-[O-(CH3)-C-11]nisoxetine was obtained in 23-29% radiochemical yields due to substantial formation of the undesired N-[C-11]methylated byproduct (64-70%). These C-11 labeled tracers allowed us to carry out comparative studies of NET in baboons with positron emission tomography (PET) and evaluate their potential as PET tracers for imaging brain NET. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2005.04.062
• 作为产物：
  描述：

  1,2-bis<(methylsulfonyl)oxy>benzene 在 氢氧化钾 作用下， 以 甲醇 、 水 为溶剂， 生成 2-(mesyloxy)phenol
  参考文献：
  名称：

  FR2289514

  摘要：

  公开号：

文献信息

• PROCESS FOR PRODUCING AROMATIC AMINES
  申请人：TAKASAGO INTERNATIONAL CORPORATION

  公开号：US20020035295A1

  公开（公告）日：2002-03-21

  The present invention provides an activator in arylamination using a palladium compound as a catalyst, which is superior to conventional phosphines in stability and performance. With the phosphine sulfide as an activator, an arylamination reaction achieves improved selectivity to produce a desired aromatic amine in an obviously increased yield as compared with a reaction using the corresponding phosphine compound. Moreover, the phosphine sulfide of the invention is impervious to oxidation and exists stably in air and therefore sufficiently withstands use on an industrial scale.

  本发明提供了一种在芳基化反应中使用钯化合物作为催化剂的活化剂，其在稳定性和性能方面优于传统的膦化合物。通过使用膦硫化物作为活化剂，芳基化反应实现了改善的选择性，以明显增加的产量生产所需的芳香胺，与使用相应的膦化合物的反应相比。此外，本发明的膦硫化物不受氧化影响，在空气中存在稳定，因此足以在工业规模上使用。
• 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst
  申请人：——

  公开号：US20020058837A1

  公开（公告）日：2002-05-16

  A novel 2,2-(diaryl)vinylphosphine compound represented by the following general formula (1): 1 (wherein R 1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alicyclic group having 5 to 7 carbon atoms, etc.; R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 may be the same or different and each is an alkyl group having 1 to 6 carbon atoms, an alicyclic group having 5 to 7 carbon atoms, etc., provided that R 4 and R 5 taken together and/or R 6 and R 7 taken together may represent a fused benzene ring, a substituted fused benzene ring, a trimethylene group, etc.; and p, q, r, and s each is 0 to 5, provided that p+q and r+s each is in the range of from 0 to 5); a palladium-phosphine catalyst obtained by causing a palladium compound to act on the novel 2,2-(diaryl)vinylphosphine compound; and a process for obtaining an arylamine, a diaryl and an arylalkyne in the presence of the palladium-phosphine catalyst.

  一种由以下通用公式（1）表示的新型2,2-(二芳基)乙烯膦化合物：其中R1是氢原子、具有1至6个碳原子的烷基基团、具有5至7个碳原子的脂环基团等；R2、R3、R4、R5、R6和R7可能相同或不同，每个是具有1至6个碳原子的烷基基团、具有5至7个碳原子的脂环基团等，但要求R4和R5一起和/或R6和R7一起可能代表融合苯环、取代融合苯环、三亚甲基基团等；p、q、r和s每个为0至5，但要求p+q和r+s分别在0至5的范围内；通过使钯化合物作用于新型2,2-(二芳基)乙烯膦化合物而获得的钯-膦催化剂；以及在钯-膦催化剂存在下获得芳胺、二芳基和芳基炔的方法。
• Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators
  申请人：Broo Anders

  公开号：US20090005353A1

  公开（公告）日：2009-01-01

  The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及公式（I）的某些新化合物，以及制备这些化合物的方法，它们在调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）以及治疗和/或预防包括心血管疾病如动脉粥样硬化，炎症性疾病，阿尔茨海默病，脂质紊乱（无论是否伴随胰岛素抵抗），2型糖尿病和代谢综合征的其他表现在内的临床疾病中的用途，以及它们的治疗使用方法和含有它们的制药组合物。
• Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
  申请人：AstraZeneca AB

  公开号：US07960380B2

  公开（公告）日：2011-06-14

  The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及某些新型化合物(I)的公式，以制备这些化合物的过程，以及它们在调节核激素受体肝X受体(LXR)α (NR1H3)和/或β (NR1H2)以及治疗和/或预防包括心血管疾病（如动脉粥样硬化）、炎症性疾病、阿尔茨海默病、脂质紊乱（无论是否与胰岛素抵抗有关）、2型糖尿病和代谢综合征的其他表现在内的临床病症方面的用途，以及它们的治疗用途的方法和含有它们的制药组合物。
• Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators
  申请人：Broo Anders

  公开号：US20100227847A1

  公开（公告）日：2010-09-09

  The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及公式（I）的某些新化合物，以及制备这些化合物的方法，它们在调节核激素受体肝X受体（LXR）α（NR1H3）和/或β（NR1H2）以及治疗和/或预防临床疾病方面具有用途，包括心血管疾病（如动脉粥样硬化），炎症性疾病，阿尔茨海默病，脂质代谢紊乱（无论是否与胰岛素抵抗有关），2型糖尿病和代谢综合征的其他表现，以及它们的治疗用途的方法和包含它们的制药组合物。